Price Chart

Profile

SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
URL https://www.sellaslifesciences.com
Investor Relations URL http://investors.galenabiopharma.com/investors/default.aspx
HQ State/Province New York
Sector Health Care
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release May. 14, 2025 (est.)
Last Earnings Release Nov. 13, 2024
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Profile

SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
URL https://www.sellaslifesciences.com
Investor Relations URL http://investors.galenabiopharma.com/investors/default.aspx
HQ State/Province New York
Sector Health Care
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release May. 14, 2025 (est.)
Last Earnings Release Nov. 13, 2024
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A